Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug.[6190728][6194059] ProMIS Therapeutics saw its stock price climb after the release of positive data from a first-of-its-kind study related to Alzheimer's disease.[6190728][6194059] The company's lead candidate for Alzheimer's treatment has shown promising results in early-stage clinical trials.[6190728]